Altimmune, Inc. remains a high-risk, high-reward play as it approaches a pivotal 48-week MASH data readout for pemvidutide. ALT's pemvidutide shows strong MASH resolution and weight loss, but has not ...
ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH. MDGL's results with its launch of MASH drug Rezdiffra demonstrate the multi-billion-dollar potential of a MASH drug, ...
In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...
Akero Therapeutics (NASDAQ:AKRO) stock soared 115% in early trading Monday after the company reported positive long-term results from a Phase 2b study of its drug efruxifermin, or EFX, in the ...
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles "The encouraging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback